Document is current
Any future updates will be listed below
-
Authors
He, Bo https://orcid.org/0000-0003-0741-0662
Wood, Kira H https://orcid.org/0009-0006-1666-9958
Li, Zhi-jie
Ermer, Judith A https://orcid.org/0000-0003-0234-9620
Li, Ji
Bastow, Edward R https://orcid.org/0009-0001-9935-1737
Sakaram, Suraj https://orcid.org/0000-0003-1841-1898
Darcy, Phillip K
Spalding, Lisa J https://orcid.org/0000-0002-3885-9625
Redfern, Cameron T
Canes, Jordi https://orcid.org/0000-0002-1309-5745
Oliveira, Mafalda
Prat, Aleix
Cortes, Javier
Thompson, Erik W https://orcid.org/0000-0002-9723-4924
Littlefield, Bruce A
Redfern, Andrew
Ganss, Ruth https://orcid.org/0000-0002-5551-045X
-
Funding
Funding for this research was provided by:
Federal Government | DHAC | National Health and Medical Research Council (1141847)
Federal Government | DHAC | National Health and Medical Research Council (2026403)
Worldwide Cancer Research (21-0257)
Federal Government | DHAC | Cancer Australia (PO411)
Federal Government | DHAC | Cancer Australia (2002303)
CCA | Cancer Council Western Australia (1168)
Australian Government
エーザイ株式会社 | Eisai Incorporated
- License Information
-
More Information
Article History
Received: 10 October 2024
Revised: 23 February 2025
Accepted: 28 February 2025
First Online: 26 March 2025
Disclosure and competing interests statement
: PKD reports research funding from Myeloid Therapeutics, Prescient Therapeutics, Bristol-Myers-Squibb and Juno Therapeutics outside of this study. MO reports research support from AstraZeneca, Ayala Pharmaceuticals, Boehringer-Ingelheim, Genentech, Gilead, GSK, Immutep, Roche, Seagen, Zenith Epigenetics; honoraria from AstraZeneca, Eisai, Gilead, Libbs, Lilly, MSD, Novartis, Pfizer, Roche, Seagen outside of this study. JC reports research support from Roche, Ariad Pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffman-La Roche, Guardanth Health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics, Iqvia; honoraria from Roche, Novartis, Eisai, Pfizer, Lilly, Merck Sharp&Dohme, Daiichi Sankyo, Astrazeneca, Gilead, Steamline Therapeutics outside of this study. BAL is an employee of Eisai Inc. which discovered, developed and now manufactures and markets the clinically formulated mesylate salt form of eribulin as Halaven ® . AR had previous roles on advisory boards and speaker engagements for Eisai Inc. outside of this study. RG is a member of the Advisory Editorial Board of EMBO Molecular Medicine. This has no bearing on the editorial consideration of this article for publication. RG received financial support from Eisai Inc. for part of this research project, and provision of eribulin for this study. The remaining authors declare no competing interests.
